the use of ropivacaine in therapeutic treatment of oral aphthosis
Clicks: 132
ID: 220759
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
132 views
26 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #963 of 1,324 articles by views in spectrochimica acta - part a: molecular and biomolecular spectroscopy
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,324 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The use of anaesthetic drugs in the treatment of oral aphthosis is one of the pharmaceutical possibilities that a doctor can use for the most painful forms. Normally, Lidocaine or Diclofenac is used to treat this disease, but they can be used for a very limited time and so they are of little practical use. In this study, the authors have used Ropivacaine whose pharmaceutical kinetics allows the analgesic effect to be active for 60 to 90 minutes. In our research, we compared 8 groups of patients who have been given 3 principal pharmaceutical products: one group was given an anaesthetic drug, one had a topical medication administered which is often used for the treatment of aphthous lesions, and the last group was given a multivitamin. These pharmaceutical products were used alone and in various possible combinations in the 8 groups. The results of this study are very interesting and show that in all the groups that used anaesthetics there was more satisfaction on the patients’ part because their pain level became more manageable right after the first application of the drug and the patients could carry on with their normal lives.
| Reference Key |
gasparini2018biomedthe
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Giulio Gasparini;Gianmarco Saponaro;Daniela Gasparini;Enrico Foresta;Camillo Azzuni;Alessia Adduci;Roberto Boniello;Alessandro Moro;Paolo De Angelis;Francesco Di Nardo;Giuseppe Damato;Piero Doneddu;Mattia Todaro;Umberto Garagiola;Sando Pelo |
| Journal | spectrochimica acta - part a: molecular and biomolecular spectroscopy |
| Year | 2018 |
| DOI |
10.1155/2018/1868254
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.